Treace Medical Concepts, Inc. (TMCI)

Market Cap	529.53M
Revenue (ttm)	202.86M
Net Income (ttm)	-61.52M
Shares Out	62.30M
EPS (ttm)	-0.99
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	93,585
Open	8.78
Previous Close	8.78
Day's Range	8.36 - 8.78
52-Week Range	3.92 - 15.98
Beta	0.66
Analysts	Hold
Price Target	7.40 (-12.94%)
Earnings Date	Nov 5, 2024

About TMCI

Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision. In addition, the company offers Adductoplasty system designed for reproducible realignment, stabi...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Apr 23, 2021
• Employees: 516
• Stock Exchange: NASDAQ
• Ticker Symbol: TMCI
• Website: https://www.treace.com

Financial Performance

In 2023, Treace Medical Concepts's revenue was $187.12 million, an increase of 31.92% compared to the previous year's $141.84 million. Losses were -$49.53 million, 15.7% more than in 2022.

Analyst Forecast

According to 6 analysts, the average rating for TMCI stock is "Hold." The 12-month stock price forecast is $7.4, which is a decrease of -12.94% from the latest price.

Price Target

$7.4

(-12.94% downside)

Analyst Consensus: Hold